
Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients : evolution, risk factors, and impact on patient outcomes
- Author
- Charlotte Defrancq, Nika De Wilde, Ann Raes (UGent) , Stephanie Van Biervliet (UGent) , Saskia Vande Velde (UGent) , Myriam Van Winckel (UGent) , Ruth De Bruyne (UGent) and Agnieszka Prytula-Ebels (UGent)
- Organization
- Abstract
- Background: This study aims to investigate the evolution and factors associated with TAC IPV and its impact on patient outcomes in pediatric LT recipients. Methods: This is a retrospective study including 41 children. The TAC IPV was expressed as the coefficient of variation and was calculated for years 1-5 following LT. The number of missed clinic appointments was used as a surrogate marker for therapy adherence. Results: We identified a decrease in the TAC IPV during the first 3 years after LT (P < 0.01). Serum albumin in the first year (P = 0.03), hematocrit (P = 0.02) and total bilirubin (P = 0.04) in the third year, and therapy adherence (P < 0.01) in the fifth year were associated with TAC IPV. High TAC IPV was associated with biopsy-proven acute allograft rejection (P = 0.04) and the need for biopsy during the first year (P = 0.02). There was a borderline association between TAC IPV and donor-specific antibodies (P = 0.08) and CMV viremia (P = 0.07). High TAC IPV was a predictor of need for liver biopsy and AR with an odds ratio of 1.04 (95% CI 1.0-1.1; P = 0.03) and 1.04 (95% CI 1.0-1.1; P = 0.05), respectively. Conclusions: Our results highlight the impact of biological factors on TAC IPV during the early LT follow-up and later also therapy adherence. High TAC IPV may be associated with adverse patient outcomes.
- Keywords
- Pediatrics, Perinatology, and Child Health, Transplantation, BLOOD-LEVELS, EVALUATING NONADHERENCE, GRAFT LOSS, HEMATOCRIT, PHARMACOKINETICS, REJECTION, MEDICATIONS, CLEARANCE, ADHERENCE, LEVEL
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 436.91 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8611624
- MLA
- Defrancq, Charlotte, et al. “Intra‐patient Variability in Tacrolimus Exposure in Pediatric Liver Transplant Recipients : Evolution, Risk Factors, and Impact on Patient Outcomes.” PEDIATRIC TRANSPLANTATION, vol. 23, no. 3, 2019, doi:10.1111/petr.13388.
- APA
- Defrancq, C., De Wilde, N., Raes, A., Van Biervliet, S., Vande Velde, S., Van Winckel, M., … Prytula-Ebels, A. (2019). Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients : evolution, risk factors, and impact on patient outcomes. PEDIATRIC TRANSPLANTATION, 23(3). https://doi.org/10.1111/petr.13388
- Chicago author-date
- Defrancq, Charlotte, Nika De Wilde, Ann Raes, Stephanie Van Biervliet, Saskia Vande Velde, Myriam Van Winckel, Ruth De Bruyne, and Agnieszka Prytula-Ebels. 2019. “Intra‐patient Variability in Tacrolimus Exposure in Pediatric Liver Transplant Recipients : Evolution, Risk Factors, and Impact on Patient Outcomes.” PEDIATRIC TRANSPLANTATION 23 (3). https://doi.org/10.1111/petr.13388.
- Chicago author-date (all authors)
- Defrancq, Charlotte, Nika De Wilde, Ann Raes, Stephanie Van Biervliet, Saskia Vande Velde, Myriam Van Winckel, Ruth De Bruyne, and Agnieszka Prytula-Ebels. 2019. “Intra‐patient Variability in Tacrolimus Exposure in Pediatric Liver Transplant Recipients : Evolution, Risk Factors, and Impact on Patient Outcomes.” PEDIATRIC TRANSPLANTATION 23 (3). doi:10.1111/petr.13388.
- Vancouver
- 1.Defrancq C, De Wilde N, Raes A, Van Biervliet S, Vande Velde S, Van Winckel M, et al. Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients : evolution, risk factors, and impact on patient outcomes. PEDIATRIC TRANSPLANTATION. 2019;23(3).
- IEEE
- [1]C. Defrancq et al., “Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients : evolution, risk factors, and impact on patient outcomes,” PEDIATRIC TRANSPLANTATION, vol. 23, no. 3, 2019.
@article{8611624, abstract = {{Background: This study aims to investigate the evolution and factors associated with TAC IPV and its impact on patient outcomes in pediatric LT recipients. Methods: This is a retrospective study including 41 children. The TAC IPV was expressed as the coefficient of variation and was calculated for years 1-5 following LT. The number of missed clinic appointments was used as a surrogate marker for therapy adherence. Results: We identified a decrease in the TAC IPV during the first 3 years after LT (P < 0.01). Serum albumin in the first year (P = 0.03), hematocrit (P = 0.02) and total bilirubin (P = 0.04) in the third year, and therapy adherence (P < 0.01) in the fifth year were associated with TAC IPV. High TAC IPV was associated with biopsy-proven acute allograft rejection (P = 0.04) and the need for biopsy during the first year (P = 0.02). There was a borderline association between TAC IPV and donor-specific antibodies (P = 0.08) and CMV viremia (P = 0.07). High TAC IPV was a predictor of need for liver biopsy and AR with an odds ratio of 1.04 (95% CI 1.0-1.1; P = 0.03) and 1.04 (95% CI 1.0-1.1; P = 0.05), respectively. Conclusions: Our results highlight the impact of biological factors on TAC IPV during the early LT follow-up and later also therapy adherence. High TAC IPV may be associated with adverse patient outcomes.}}, articleno = {{e13388}}, author = {{Defrancq, Charlotte and De Wilde, Nika and Raes, Ann and Van Biervliet, Stephanie and Vande Velde, Saskia and Van Winckel, Myriam and De Bruyne, Ruth and Prytula-Ebels, Agnieszka}}, issn = {{1397-3142}}, journal = {{PEDIATRIC TRANSPLANTATION}}, keywords = {{Pediatrics,Perinatology,and Child Health,Transplantation,BLOOD-LEVELS,EVALUATING NONADHERENCE,GRAFT LOSS,HEMATOCRIT,PHARMACOKINETICS,REJECTION,MEDICATIONS,CLEARANCE,ADHERENCE,LEVEL}}, language = {{eng}}, number = {{3}}, pages = {{7}}, title = {{Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients : evolution, risk factors, and impact on patient outcomes}}, url = {{http://doi.org/10.1111/petr.13388}}, volume = {{23}}, year = {{2019}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: